

For the source and calculation basis of Fund information, please refer to the \*Explanatory Notes section.

## Fund Overview

Base Currency for Fund	USD
Total Net Assets (USD)	2.13 billion
Fund Inception Date	03.04.2000
Number of Issuers	93
Benchmark	NASDAQ Biotechnology Index
Morningstar Category™*	Sector Equity Biotechnology

## Summary of Investment Objective

The Fund aims to achieve capital appreciation by investing principally in equity securities of biotechnology companies and discovery research firms mainly located in the US.

## Fund Management\*

Evan McCulloch, CFA: United States  
Wendy Lam, PhD: United States  
Steve Kornfeld, CFA: United States

## Ratings - A (acc) USD

Overall Morningstar Rating™\*: ★★★★★

## Asset Allocation\*

	%
Equity	98.64
Cash & Cash Equivalents	1.36

## Offering Documents



## Risk Considerations

- The Fund may invest in small and mid-sized companies, and as a result may be subject to lower liquidity and more volatility than funds investing wholly in larger companies.
- The Fund invests primarily in a single sector, and is subject to higher concentration risk and as a result may be more volatile than funds following a more diversified policy.
- The Fund's value may be affected by exchange control regulations and changes in exchange rates.
- This investment involves risks which may result in loss of part or entire amount of your investment.
- Before you decide to invest, you should make sure the intermediary has explained to you that the Fund is suitable to you.
- Investors should not only base on this marketing material alone to make investment decisions.

## Performance\*

### Performance over 5 Years in Share Class Currency (%)

■ Franklin Biotechnology Discovery Fund A (acc) USD



### Performance in Share Class Currency (%)

	Cumulative						
	3 Mths	YTD	1 Yr	3 Yrs	5 Yrs	10 Yrs	Since Incept
A (acc) USD	7.55	9.42	4.02	0.88	68.63	274.27	246.20
Benchmark in USD	12.77	14.48	10.07	7.35	90.38	339.53	260.72

### Calendar Year Performance in Share Class Currency (%)

	2017	2016	2015	2014	2013
A (acc) USD	16.93	-17.87	4.93	34.70	64.27
Benchmark in USD	21.06	-21.68	11.42	34.32	65.97

## Top Ten Holdings (% of Total)

Issuer Name	%
CELGENE CORP	6.93
ALEXION PHARMACEUTICALS INC	6.77
BIOGEN INC	5.83
VERTEX PHARMACEUTICALS INC	5.52
ILLUMINA INC	5.27
REGENERON PHARMACEUTICALS INC	3.84
GILEAD SCIENCES INC	3.18
AMGEN INC	3.16
NEUROCRINE BIOSCIENCES INC	2.93
HERON THERAPEUTICS INC	2.82

## Fund Measures

P/E to Growth	1.23x
Historical 3 Yr Sales Growth	31.69%
Estimated 3-5 Yr EPS Growth (Forward)	27.20%
Price to Earnings (12-mo Forward)	18.78x
Standard Deviation (5 Yrs)	23.26%

## Share Class Information

Share Class	Incept Date	NAV	TER (%)	Fees				Dividends		Fund Identifiers
				Max. Sales Charge (%)	Mgmt. Fee (%)	Max. Maint. Charge (%)	Max. Serv. Charge (%)	Last Paid Date	Last Paid Amount	ISIN
A (acc) USD	03.04.2000	USD 34.62	1.82	5.00	1.00	0.50	N/A	N/A	N/A	LU0109394709
A (acc) HKD	26.02.2013	HKD 22.65	1.82	5.00	1.00	0.50	N/A	N/A	N/A	LU0889565916
B (acc) USD	03.04.2000	USD 27.37	3.13	N/A	1.00	0.75	1.06	N/A	N/A	LU0109394881

For the source and calculation basis of Fund information, please refer to the \*Explanatory Notes section.

### Composition of Fund\*

Market Capitalisation Breakdown in USD	% of Equity
<2.0 Billion	25.66
2.0-5.0 Billion	17.88
5.0-10.0 Billion	5.90
10.0-25.0 Billion	8.74
25.0-50.0 Billion	16.35
>50.0 Billion	24.70
N/A	0.78

### Important Information

Unless stated otherwise, all information is as of the publishing date of this document. Source: Franklin Templeton Investments.

Franklin Templeton Investments (Asia) Limited is the issuer of this document. This document is neither an offer nor solicitation to purchase shares of the fund; applications for shares may only be made on forms of application available with the Offering Documents. Investments are subject to investment risks, fund value may go up as well as down and past performance is not an indicator or a guarantee of future performance. The investment returns are denominated in fund currency. Investors investing in funds denominated in non-local currency should be aware of the risk of exchange rate fluctuations that may cause a loss of principal. Investors should read carefully the Offering Documents (including the section 'Risk Considerations') for the relevant risks associated with the investment in the fund before investing. Distribution of this document may be restricted in certain jurisdictions. This document does not constitute the distribution of any information or the making of any offer or solicitation by anyone in any jurisdiction in which such distribution or offer is not authorized or to any person to whom it is unlawful to distribute such a report or make such an offer or solicitation. This document has not been reviewed by the Securities and Futures Commission of Hong Kong.

### \*Explanatory Notes

**Performance:** Performance information is based on the stated share class only, in Fund Currency, NAV to NAV, taking into account of dividend reinvestments and capital gain or loss.

When performance for either the portfolio or its benchmark has been converted, different foreign exchange closing rates may be used between the portfolio and its benchmark.

**Morningstar Category™:** Copyright © Morningstar, Inc. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is provided for reference purposes only. Past performance is not an indicator or a guarantee of future performance.

**Fund Management:** In the case of portfolio managers who are CFA Charterholders, CFA® and Chartered Financial Analyst® are trademarks owned by CFA Institute.

**Ratings:** Copyright © Morningstar, Inc. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is provided for reference purposes only. Past performance is not an indicator or a guarantee of future performance.

**Top 10 Holdings:** These securities do not represent all of the securities purchased, sold or recommended for clients, and the reader should not assume that investment in the securities listed was or will be profitable. The portfolio manager for the Fund reserves the right to withhold release of information with respect to holdings that would otherwise be included in the top holdings list.

**Asset Allocation/Composition of Fund:** Due to rounding, the sum of portfolio may not equal 100%.